Doxorubicin (Doxo) is a widely used chemotherapeutic drug for cancer, though it can have toxic effects on the heart. A recent animal study published in The FASEB Journal investigated whether the cardioregulatory protein chromogranin A (CgA) contributes to the regulation of the cardiotoxic and antitumor activities of Doxo.
To conduct the study, a group of researchers used several in vivo and ex vivo murine models. A rat model was employed to study cardioprotection of CgA in the presence of Doxo, while a mouse model was used to monitor antitumor activities. The study proved that during treatment with Doxo, the release of CgA in the blood was reduced. In addition, when the plasma levels of CgA were restored, the heart was protected from Doxo-dependent cardiotoxicity without impairing the antitumor effect of Doxo.
Together, these findings suggest that monitoring plasma levels of CgA before and after chemotherapy in cancer patients might provide important prognostic information regarding drug-related cardiotoxicity.
"Detection of circulating CgA before, during, and after therapy with Doxo can predict cardiotoxicity," said Tommaso Angelone, PhD, a professor of physiology at the Lab of Cellular and Molecular Cardiac Patho-physiology within the University of Calabria's Department of Biology, Ecology and Earth Sciences in Italy. "Administration of CgA to cancer patients with low CgA plasma levels might represent a novel pharmacological strategy to limit cardiac damage typically associated with therapies such as Doxo."
"We tend to think primarily of gastrointestinal disturbance and hair loss in cancer chemotherapy, but cardiotoxicity can be far more serious in overall morbidity. This study is thus a most welcome development," said Thoru Pederson, PhD, Editor-in-Chief of The FASEB Journal.
###
The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). The world's most cited biology journal according to the Institute for Scientific Information, it has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.
FASEB is composed of 29 societies with more than 130,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to member societies and their members.
Journal
The FASEB Journal